Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 18,606,743		$ 20,318,411
Accounts receivable, net of allowances of $572,500 at September 30, 2016 and $0 at December 31, 2015	4,274,800		2,566,101
Deferred costs	4,315,977		2,911,743
Prepaid expenses and other current assets	2,767,243		3,476,177
Total current assets	29,964,763		29,272,432
Property, plant and equipment, net	17,123,693		17,064,900
Goodwill	7,013,315		7,013,315
Intangible assets, net	2,450,380		2,877,880
Other assets	726,787		976,768
Total assets	57,278,938		57,205,295
Current Liabilities
Accounts payable	3,245,779		4,107,388
Accrued liabilities	6,372,789		6,198,488
Long-term debt, current	2,319,844		4,171,456
Notes payable, current	745,234		1,192,666
Unearned revenues	5,869,586		5,345,225
Total current liabilities	18,553,232		21,015,223
Long-term Liabilities
Deferred income taxes	1,079,948		932,662
Notes payable	224,722		583,041
Unearned revenues - long-term	4,329,950		0
Long-term debt	3,331,510		10,828,544
Other long-term liabilities	370,081		562,001
Total liabilities	27,889,443		33,921,471
Commitments and Contingencies (see Note 15)
Redeemable Securities	19,400,000		0
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2016 and December 31, 2015	100		100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 8,181,921 and 5,673,302 shares, at September 30, 2016 and December 31, 2015, respectively	8,182		5,673
Additional paid-in capital	410,276,001		396,547,401
Treasury stock, at cost; 10,999 shares at September 30, 2016 and December 31, 2015, respectively	(707,637)		(707,637)
Accumulated deficit	(398,830,656)		(372,132,490)
Accumulated other comprehensive income	0		486
Total Caladrius Biosciences, Inc. stockholders' equity	10,745,990		23,713,533
Noncontrolling interests	(756,495)		(429,709)
Total equity	9,989,495		23,283,824
Liabilities and Equity, Total	$ 57,278,938		$ 57,205,295